A pravastatin dose-escalation study in systemic lupus erythematosus

被引：43

作者：

Costenbader, Karen H.

Liang, Matthew H.

Chibnik, Lori B.

Aizer, Juliet

Kwon, Hannah

Gall, Victoria

Karlson, Elizabeth W.

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Sect Clin Sci,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA

[2] Weill Cornell Med Coll, Hosp Special Surg, Div Rheumatol, New York, NY 10021 USA

[3] Univ Calif San Francisco, Dept Anesthesia & Preoperat Care, San Francisco, CA 94143 USA

来源：

RHEUMATOLOGY INTERNATIONAL | 2007年 / 27卷 / 11期

基金：

美国国家卫生研究院;

关键词：

systemic lupus erythematosus; atherosclerosis; prevention; statin; cholesterol;

D O I：

10.1007/s00296-007-0341-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/- 12.1%) and LDL by 24% (+/- 17%), compared with 1.8% (+/- 7.5%) and 2.6% (+/- 8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.

引用

页码：1071 / 1077

页数：7

共 44 条

[21] MEASUREMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS ACTIVITY IN CLINICAL RESEARCH [J].

LIANG, MH ;

SOCHER, SA ;

ROBERTS, WN ;

ESDAILE, JM .

ARTHRITIS AND RHEUMATISM, 1988, 31 (07) :817-825

[22] Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease [J].

Lieberman, EH ;

Gerhard, MD ;

Uehata, A ;

Selwyn, AP ;

Ganz, P ;

Yeung, AC ;

Creager, MA .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (11) :1210-1214

[23]

Manzi S, 1997, AM J EPIDEMIOL, V145, P408

[24] Current perspectives on statins [J].

Maron, DJ ;

Fazio, S ;

Linton, MF .

CIRCULATION, 2000, 101 (02) :207-213

[25] Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury [J].

Mason, JC ;

Ahmed, Z ;

Mankoff, R ;

Lidington, EA ;

Ahmad, S ;

Bhatia, V ;

Kinderlerer, A ;

Randi, AM ;

Haskard, DO .

CIRCULATION RESEARCH, 2002, 91 (08) :696-703

[26]

Masuho Y, 2001, BJU INT, V88, P11

[27] Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial [J].

McCarey, DW ;

McInnes, LB ;

Madhok, R ;

Hampson, R ;

Scherbakova, O ;

Ford, I ;

Capell, HA ;

Sattar, N .

LANCET, 2004, 363 (9426) :2015-2021

[28] Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial [J].

Nissen, SE ;

Nicholls, SJ ;

Sipahi, I ;

Libby, P ;

Raichlen, JS ;

Ballantyne, CM ;

Davignon, J ;

Erbel, R ;

Fruchart, JC ;

Tardif, JC ;

Schoenhagen, P ;

Crowe, T ;

Cain, V ;

Wolski, K ;

Goormastic, M ;

Tuzcu, EM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1556-1565

[29] Risks and benefits of statins in lupus erythematosus [J].

Noël, B .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) :107-108

[30] RISK-FACTORS FOR CORONARY-ARTERY DISEASE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].

PETRI, M ;

PEREZGUTTHANN, S ;

SPENCE, D ;

HOCHBERG, MC .

AMERICAN JOURNAL OF MEDICINE, 1992, 93 (05) :513-519

← 1 2 3 4 5 →